Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study.
Authors
Valle, Juan WDangoor, Adam
Beech, Janette
Sherlock, David J
Lee, Siow Ming
Scarffe, J Howard
Swindell, Ric
Ranson, Malcolm R
Affiliation
Christie Hospital NHS Trust, Manchester, Wilmslow Road, Manchester M20 4BX, UK. juan.valle@christie-tr.nwest.nhs.ukIssue Date
2005-02-28
Metadata
Show full item recordAbstract
Monthly intravenous pegylated liposomal doxorubicin (PLD) 50 mg m(-2), although well tolerated, showed almost no activity in this phase II study of 16 patients with advanced hepatocellular carcinoma with a response rate of 0%, stable disease 19%, median time to progression of 2.4 months, 1-year survival of 25% and median survival of 6.5 months.Citation
Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. 2005, 92 (4):628-30 Br. J. CancerJournal
British Journal of CancerDOI
10.1038/sj.bjc.6602394PubMed ID
15700038Type
ArticleLanguage
enISSN
0007-0920ae974a485f413a2113503eed53cd6c53
10.1038/sj.bjc.6602394
Scopus Count
Collections
Related articles
- Pegylated liposomal doxorubicin-based combination chemotherapy as salvage treatment in patients with advanced hepatocellular carcinoma.
- Authors: Poh SB, Bai LY, Chen PM
- Issue date: 2005 Dec
- Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma.
- Authors: Schmidinger M, Wenzel C, Locker GJ, Muehlbacher F, Steininger R, Gnant M, Crevenna R, Budinsky AC
- Issue date: 2001 Dec 14
- Activity and safety of pegylated liposomal doxorubicin, 5-fluorouracil and folinic acid in inoperable hepatocellular carcinoma: a phase II study.
- Authors: Di Lorenzo G, Rea A, Carlomagno C, Pepe S, Palmieri G, Labianca R, Chirianni A, De Stefano A, Esposito V, De Placido S, Montesarchio V
- Issue date: 2007 Dec 28
- A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma.
- Authors: Hong RL, Tseng YL
- Issue date: 2003 May
- Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
- Authors: Skubitz KM, Blaes AH, Konety SH, Francis GS
- Issue date: 2017 Oct